Cognition Therapeutics Inc (CGTX) stock
CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.58−0.02 (-3.06%)
Close on Nov 20, 2026Market cap $55.36MP/E –Yield –
Cognition Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Cognition Therapeutics's free cash flow for the twelve months ending Dec 31, 2024 was -$28.48M. For fiscal 2024 it was -$28.48M. The highest annual figure on record is -$3.44M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$28.48M | – |
| FY2023 | Dec 31, 2023 | -$16.17M | – |
| FY2022 | Dec 31, 2022 | -$18.70M | – |
| FY2021 | Dec 31, 2021 | -$3.66M | – |
| FY2020 | Dec 31, 2020 | -$3.44M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -$8.38M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.85M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.49M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.22M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.71M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.75M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.19M | – |
| Q3 FY2022 | Sep 30, 2022 | -$27.00K | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.36M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.12M | – |
| Q4 FY2020 | Dec 31, 2020 | -$480.00K | – |
See a number that looks wrong?